Jupiter Wellness Prices $32.5 Million Underwritten Public Offering of Common Stock and Warrants

JUPITER, FL / July 21, 2021 / Jupiter Wellness, Inc. (the “Company”) (NASDAQ:JUPW), today announced the pricing of an underwritten public offering (the “Offering”) of 11,066,258 shares (the “Company Offering Shares”) of common stock, par value $0.001 per share (“Common Stock”) to be issued by the Company, 540,884 shares (the “Selling Stockholder Shares”) of Common […]

Jupiter Wellness Announces Appointment of Dr. Andy Goren to Scientific Advisory Board

JUPITER, FL / July 15, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that Dr Andy Goren has been appointed to its Scientific Advisory Board. Dr. Andy Goren has more than twenty years of experience in clinical research, development, and commercialization of breakthrough therapeutics and diagnostics. Among his list of many firsts in dermatology, Dr. […]

Jupiter Wellness Announces initiation of Head-to-Head Trial Comparing JW-100 and Eucrisa(R) for the Treatment of Mild-to-Moderate Eczema

JUPITER, FL / July 13, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema. JW-100 […]

Jupiter Wellness Licenses Photocil(TM), a Novel Topical Treatment of Psoriasis, Vitiligo, Pruritis and Atopic Dermatitis

*Photo-Therapy in a tub JUPITER, FL / July 9, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced they have entered into an exclusive agreement to license Photocil™, a novel patented topical cream that provides clinically-proven relief for Psoriasis, Vitiligo and Atopic Dermatitis. The Agrement signed with the Applied Biology (“AB”) whereby Jupiter Wellness is the […]

Results of Clinical Study Showing That JW 100 Significantly Reduces ISGA Score in Atopic Dermatitis (AD) Published

https://pubmed.ncbi.nlm.nih.gov/34056830/ JUPITER, FL / June 22, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced the publication of clinical study results to investigate the safety and efficacy of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema). J Cosmet Dermatol 2021 May 31: Online ahead of print. The peer-reviewed publication reports on a […]

Jupiter Wellness Licenses Patents for the Treatment of Contact Dermatitis

JUPITER, FL / June 17, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a licensing agreement for two patents covering the use of Aspartame for the treatment of Contact Dermatitis. The Agreement signed with the Oklahoma Medical Research Foundation is for a license to two issued patents, US, 7,288,527 and US 7,816,327 which cover the […]

Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments

Four Indications in Clinical Development JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced an update on its clinical pipeline of CBD-based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 […]

Jupiter Wellness Enters into Letter of Intent to Acquire JustCBD and its Affiliates

Accretive acquisition would add a profitable company with approximately $28 million of revenue in 2020 (unaudited) JUPITER, FL / ACCESSWIRE / April 20, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has signed a non-binding Letter of Intent with JustCBD and its […]

Jupiter Wellness to Support Growth in CBD-Based Pharma & Consumer Products

JUPITER, FL / ACCESSWIRE / April 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Over the past quarters, Jupiter […]